4.7 Article

Conversion of α-Amino Acids into Bioactive o-Aminoalkyl Resorcylates and Related Dihydroxyisoindolinones

期刊

JOURNAL OF ORGANIC CHEMISTRY
卷 76, 期 15, 页码 6209-6217

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jo2009356

关键词

-

资金

  1. Engineering and Physical Sciences Research Council (EPSRC)
  2. GlaxoSmithKline

向作者/读者索取更多资源

The synthesis of biologically active o-aminoalkyl resorcylates and related dihydroxyisoindolinones from functionalized alpha-amino acids without the use of phenolic protection is described. The key aminoalkyl-diketo-dioxinone intermediates were prepared utilizing a crossed Claisen condensation reaction in the presence of diethylzinc. The aromatic unit was constructed via late stage cyclization and aromatization, and subsequent modification provided the novel resorcylates which showed activity against a selection of receptors and kinases, including 5-HT and CDK.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

Zheqi Li, Yang Wu, Megan E. Yates, Nilgun Tasdemir, Amir Bahreini, Jian Chen, Kevin M. Levine, Nolan M. Priedigkeit, Azadeh Nasrazadani, Simak Ali, Laki Buluwela, Spencer Arnesen, Jason Gertz, Jennifer K. Richer, Benjamin Troness, Dorraya El-Ashry, Qiang Zhang, Lorenzo Gerratana, Youbin Zhang, Massimo Cristofanilli, Maritza A. Montanez, Prithu Sundd, Callen T. Wallace, Simon C. Watkins, Caterina Fumagalli, Elena Guerini-Rocco, Li Zhu, George C. Tseng, Nikhil Wagle, Jason S. Carroll, Paul Jank, Carsten Denkert, Maria M. Karsten, Jens-Uwe Blohmer, Ben H. Park, Peter C. Lucas, Jennifer M. Atkinson, Adrian Lee, Steffi Oesterreich

Summary: This study demonstrated the potential role of ESR1 mutations in distant recurrence of breast cancer. Through transcriptomic profiling and functional experiments, it was shown that ESR1 mutations altered the cell adhesive gene network, leading to enhanced cell-cell contacts and decreased cell-extracellular matrix adhesion. Additionally, ESR1-mutant cells formed larger and more compact multicellular circulating tumor cell clusters in vivo, and ESR1 mutations were associated with enrichment of circulating tumor cell clusters in metastatic breast cancer patients.

CANCER RESEARCH (2022)

Article Biochemistry & Molecular Biology

Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer

Simon C. Baker, Andrew S. Mason, Raphael G. Slip, Katie T. Skinner, Andrew Macdonald, Omar Masood, Reuben S. Harris, Tim R. Fenton, Manikandan Periyasamy, Simak Ali, Jennifer Southgate

Summary: Limited understanding of bladder cancer aetiopathology hampers progress in reducing incidence. This study provides missing mechanistic evidence linking reactivated BKPyV-infection to bladder cancer risk.

ONCOGENE (2022)

Meeting Abstract Oncology

A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Sacha J. Howell, Laura M. Kenny, Simon Lord, Matthew G. Krebs, Tobias Arkenau, Richard Baird, Iain R. MacPherson, Ash Bahl, Glen Clack, Edward Ainscow, Anthony G. M. Barrett, Paul A. Dickinson, Matthew J. Fuchter, Manfred Lehnert, Simak Ali, Stuart McIntosh, Charles Coombes

CANCER RESEARCH (2022)

Meeting Abstract Oncology

Esr1 mutant breast cancers show elevated basal cytokeratins and immune activation

Zheqi Li, Yang Wu, Olivia Mcginn, Amir Bahreini, Nolan M. Priedigkeit, Kai Ding, Sayali Onkar, Carol A. Sartorius, Lori Miller, Margaret Rosenzweig, Nikhil Wagle, Jennifer K. Richer, William J. Muller, Laki Buluwela, Simak Ali, Dario A. A. Vignali, Yusi Fang, Li Zhu, George C. Tseng, Jason Gertz, Jennifer M. Atkinson, Adrian V. Lee, Steffi Oesterreich

CANCER RESEARCH (2022)

Article Multidisciplinary Sciences

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Zheqi Li, Olivia McGinn, Yang Wu, Amir Bahreini, Nolan M. Priedigkeit, Kai Ding, Sayali Onkar, Caleb Lampenfeld, Carol A. Sartorius, Lori Miller, Margaret Rosenzweig, Ofir Cohen, Nikhil Wagle, Jennifer K. Richer, William J. Muller, Laki Buluwela, Simak Ali, Tullia C. Bruno, Dario A. A. Vignali, Yusi Fang, Li Zhu, George C. Tseng, Jason Gertz, Jennifer M. Atkinson, Adrian Lee, Steffi Oesterreich

Summary: Mutations in ESR1 gene are associated with acquired resistance to therapy in luminal breast cancer. ESR1 mutant tumors gain basal-like features and show increased expression of basal cytokeratines and immune activation. These mutations are linked to intrinsic subtype switching and may be targeted for immune therapeutic vulnerabilities.

NATURE COMMUNICATIONS (2022)

Correction Multidisciplinary Sciences

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (vol 13, 3246, 2022)

R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. Ferguson, M. J. Seckl

NATURE COMMUNICATIONS (2023)

Article Oncology

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Ellen Olden, Lucy Penfold, Simon Ang, Alice Ormrod, Damien A. Leach, Chun-Fui Lai, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter, Simak Ali, Charlotte L. Bevan

Summary: This study demonstrates that the CDK7 inhibitor CT7001 selectively inhibits proliferation and cell cycle in prostate cancer cells, and exerts antitumor effects by activating p53, inducing apoptosis, and suppressing transcription mediated by full-length and constitutively active AR splice variants. Oral administration of CT7001 suppresses the growth of CRPC xenografts, and significantly enhances the growth inhibition achieved by enzalutamide. Transcriptome analyses indicate that the mode of action of CT7001 in vivo is through inhibition of the cell cycle and AR function.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo

Lubaid Saleh, Penelope D. Ottewell, Janet E. Brown, Steve L. Wood, Nichola J. Brown, Caroline Wilson, Catherine Park, Simak Ali, Ingunn Holen

Summary: CDK4/6 inhibitor palbociclib significantly impedes tumour growth in murine models of both estrogen receptor positive and triple negative bone metastatic breast cancer when given daily. However, tumour cells become insensitive to palbociclib after a treatment break, and the levels of key proteins may play a role in this.

CANCERS (2023)

Correction Multidisciplinary Sciences

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (vol 14, 4444, 2023)

R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

R. Charles Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

Summary: This study reports the clinical trial results of samuraciclib as an anti-cancer treatment, showing its clinical activity in patients with triple negative breast cancer and HR+/HER2- breast cancer.

NATURE COMMUNICATIONS (2023)

Article Biochemistry & Molecular Biology

Selective inhibition of CDK9 in triple negative breast cancer

Ebtihal H. Mustafa, Geraldine Laven-Law, Zoya Kikhtyak, Van Nguyen, Simak Ali, Alex A. Pace, Richard Iggo, Alemwork Kebede, Ben Noll, Shudong Wang, Jean M. Winter, Amy R. Dwyer, Wayne D. Tilley, Theresa E. Hickey

Summary: Targeting transcription via CDK9 could be a potential therapeutic strategy for TNBC. Preclinical studies showed that a selective CDK9 inhibitor, CDDD11-8, effectively inhibited proliferation, induced cell cycle arrest, and increased apoptosis of TNBC cells in vitro and in vivo, without apparent toxicity to normal tissues.

ONCOGENE (2023)

Article Oncology

Circulating neutrophils from patients with early breast cancer have distinct subtype-dependent phenotypes

Anisha Ramessur, Bana Ambasager, Iker Valle Aramburu, Freddie Peakman, Kelly Gleason, Christoph Lehmann, Venizelos Papayannopoulos, Raoul Charles Coombes, Ilaria Malanchi

Summary: An elevated number of circulating neutrophils is a poor prognostic factor for breast cancer, and bone marrow activation is found to be involved. However, it is unclear how early this activation can be detected. In this study, we found subtype-specific changes in circulating neutrophils and perturbations in their overall kinase activity in newly diagnosed breast cancer patients. Different subtypes of breast cancer patients exhibited distinct neutrophil kinase activity patterns, and the lifespan of neutrophils also increased in cancer patients. These results suggest that the kinase activation patterns in circulating neutrophils may be used as markers to differentiate cancer patients from those with benign breast lesions.

BREAST CANCER RESEARCH (2023)

Meeting Abstract Chemistry, Multidisciplinary

Harnessing the power of cryo-EM for development of cancer therapeutics: High-resolution structures of the human CDK-activating kinase bound to inhibitors

Basil Greber, Victoria Cushing, Junjie Feng, Adrian Koh, Abhay Kotecha, Matthew Fuchter, Simak Ali

ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2022)

暂无数据